Acadia stock falls after Phase 3 PWS trial fails to meet primary endpoint
NegativeFinancial Markets

Acadia Pharmaceuticals faced a setback as its stock dropped following the failure of its Phase 3 trial for PWS, which did not meet its primary endpoint. This news is significant as it raises concerns about the company's future prospects and the effectiveness of its treatment, impacting investor confidence and potentially delaying advancements in therapies for Prader-Willi Syndrome.
— Curated by the World Pulse Now AI Editorial System